BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34249954)

  • 1. Cytokine Consistency Between Bone Marrow and Peripheral Blood in Patients With Philadelphia-Negative Myeloproliferative Neoplasms.
    Chen P; Wu B; Ji L; Zhan Y; Li F; Cheng L; Cao J; Chen H; Ke Y; Min Z; Sun L; Hua F; Chen H; Cheng Y
    Front Med (Lausanne); 2021; 8():598182. PubMed ID: 34249954
    [No Abstract]   [Full Text] [Related]  

  • 2. Bone Marrow Soluble Mediator Signatures of Patients With Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Cominal JG; Cacemiro MDC; Berzoti-Coelho MG; Pereira IEG; Frantz FG; Souto EX; Covas DT; de Figueiredo-Pontes LL; Oliveira MC; Malmegrim KCR; de Castro FA
    Front Oncol; 2021; 11():665037. PubMed ID: 34084749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proliferative characteristics of Philadelphia-negative myeloproliferative neoplasms - clinical implications.
    Šefer D; Bižić-Radulović S; Kraguljac-Kurtović N; Bogdanović A; Čokić V; Miljić P; Beleslin-Čokić B; Knežević V; Mitrović-Ajtić O; Leković D; Gotić M
    Int J Lab Hematol; 2017 Feb; 39(1):21-31. PubMed ID: 28025866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients.
    Cao Y; Luetkens T; Kobold S; Hildebrandt Y; Gordic M; Lajmi N; Meyer S; Bartels K; Zander AR; Bokemeyer C; Kröger N; Atanackovic D
    Exp Hematol; 2010 Oct; 38(10):860-7. PubMed ID: 20619313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneity of the bone marrow niche in patients with myeloproliferative neoplasms: ActivinA secretion by mesenchymal stromal cells correlates with the degree of marrow fibrosis.
    Rambaldi B; Diral E; Donsante S; Di Marzo N; Mottadelli F; Cardinale L; Dander E; Isimbaldi G; Pioltelli P; Biondi A; Riminucci M; D'Amico G; Elli EM; Pievani A; Serafini M
    Ann Hematol; 2021 Jan; 100(1):105-116. PubMed ID: 33089365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Inflammatory Factors during Disease Pathogenesis and Stem Cell Transplantation in Myeloproliferative Neoplasms.
    Chatain N; Koschmieder S; Jost E
    Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32806517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Altered serum cytokine expression profile in systemic sclerosis and its regulatory mechanisms].
    Zhu HL; DU Q; Chen WL; Zuo XX; Li QZ; Liu SJ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Aug; 51(4):716-722. PubMed ID: 31420628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flow cytometry immunophenotypic analysis of Philadelphia-negative myeloproliferative neoplasms: Correlation with histopathologic features.
    Ouyang J; Zheng W; Shen Q; Goswami M; Jorgensen JL; Medeiros LJ; Wang SA
    Cytometry B Clin Cytom; 2015; 88(4):236-43. PubMed ID: 25557358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokines frequently implicated in myeloproliferative neoplasms.
    Wang Y; Zuo X
    Cytokine X; 2019 Mar; 1(1):100005. PubMed ID: 33604548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disseminated tumor cells and enhanced level of some cytokines in bone marrow and peripheral blood of breast cancer patients as predictive factors of tumor progression.
    Semesiuk NI; Zhylchuk A; Bezdenezhnykh N; Lykhova A; Vorontsova AL; Zhylchuk VE; Kudryavets YI
    Exp Oncol; 2013 Dec; 35(4):295-302. PubMed ID: 24382441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
    Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The morphology features of bone marrow in the prefibrotic-early primary myelofibrosis].
    Gong XB; Zhang XH; Lu XG; Tang QS; Gao X; Yang J
    Zhonghua Xue Ye Xue Za Zhi; 2012 Jan; 33(1):25-30. PubMed ID: 22575188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic polymorphisms and expression of NLRP3 inflammasome-related genes are associated with Philadelphia chromosome-negative myeloproliferative neoplasms.
    Zhou Y; Yan S; Liu N; He N; Zhang A; Meng S; Ji C; Ma D; Ye J
    Hum Immunol; 2020; 81(10-11):606-613. PubMed ID: 32981742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macrophage frequency in the bone marrow correlates with morphologic subtype of myeloproliferative neoplasm.
    Molitor DCA; Boor P; Buness A; Schneider RK; Teichmann LL; Körber RM; Horvath GL; Koschmieder S; Gütgemann I
    Ann Hematol; 2021 Jan; 100(1):97-104. PubMed ID: 33104881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study.
    Tefferi A; Vaidya R; Caramazza D; Finke C; Lasho T; Pardanani A
    J Clin Oncol; 2011 Apr; 29(10):1356-63. PubMed ID: 21300928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flow cytometry immunophenotypic analysis of Philadelphia-negative myeloproliferative neoplasms: Correlation with histopathologic features.
    Ouyang J; Zheng W; Shen Q; Goswami M; Jorgensen JL; Medeiros LJ; Wang SA
    Cytometry B Clin Cytom; 2014 Dec; ():. PubMed ID: 25504846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canonical Wnt/β-Catenin Signaling Pathway Is Dysregulated in Patients With Primary and Secondary Myelofibrosis.
    Lucijanic M; Livun A; Tomasovic-Loncaric C; Stoos-Veic T; Pejsa V; Jaksic O; Prka Z; Kusec R
    Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):523-526. PubMed ID: 27381374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Differences in immune damage between patients with severe fever with thrombocytopenia syndrome and patients with tsutsugamushi disease].
    Hu L; Kong Q; Yue C; He L; Xia L; Li J
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Aug; 32(8):947-952. PubMed ID: 32912408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow microvessel density and plasma angiogenic factors in myeloproliferative neoplasms: clinicopathological and molecular correlations.
    Lekovic D; Gotic M; Skoda R; Beleslin-Cokic B; Milic N; Mitrovic-Ajtic O; Nienhold R; Sefer D; Suboticki T; Buac M; Markovic D; Diklic M; Cokic VP
    Ann Hematol; 2017 Mar; 96(3):393-404. PubMed ID: 27924369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.